Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update
M Kudo - Liver Cancer, 2020 - karger.com
Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the
introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the …
introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the …
Systemic treatment of HCC in special populations
L Rimassa, N Personeni, C Czauderna, F Foerster… - Journal of …, 2021 - Elsevier
Recent years have seen significant progress in the systemic treatment of hepatocellular
carcinoma (HCC), including the advent of immunotherapy. While several large phase III …
carcinoma (HCC), including the advent of immunotherapy. While several large phase III …
Phase I trial of a glypican-3–derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival
Y Sawada, T Yoshikawa, D Nobuoka, H Shirakawa… - Clinical Cancer …, 2012 - AACR
Purpose: The carcinoembryonic antigen glypican-3 (GPC3) is an ideal target of anticancer
immunotherapy against hepatocellular carcinoma (HCC). In this nonrandomized, open …
immunotherapy against hepatocellular carcinoma (HCC). In this nonrandomized, open …
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
YC Shen, DL Ou, C Hsu, KL Lin, CY Chang… - British journal of …, 2013 - nature.com
Background: Sorafenib is the only drug approved for the treatment of hepatocellular
carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to …
carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to …
Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study
S Shimose, H Iwamoto, T Niizeki, T Shirono, Y Noda… - Cancers, 2020 - mdpi.com
We sought to investigate the clinical profile (s) associated with the discontinuation of
lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable …
lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable …
[HTML][HTML] By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice
W Dai, F Wang, J Lu, Y Xia, L He, K Chen, J Li, S Li… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Cancer cells exhibit an altered metabolic phenotype known as the aerobic glycolysis. The
expression of HK2 changes the metabolic phenotype of cells to support cancerous growth …
expression of HK2 changes the metabolic phenotype of cells to support cancerous growth …
In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of …
S Li, L Wu, J Feng, J Li, T Liu, R Zhang, S Xu… - Scientific reports, 2016 - nature.com
Glycolysis, as an altered cancer cell-intrinsic metabolism, is an essential hallmark of cancer.
Phosphofructokinase (PFK) is a metabolic sensor in the glycolytic pathway and restricting …
Phosphofructokinase (PFK) is a metabolic sensor in the glycolytic pathway and restricting …
A review of hepatocellular carcinoma in elderly patients focused on management and outcomes
E Cho, HA Cho, CH Jun, HJ Kim, SB Cho, SK Choi - in vivo, 2019 - iv.iiarjournals.org
Recent studies report a significant age-specific increase in hepatocellular carcinoma (HCC)
development among persons over 75 years old. Therefore, there is an urgent need to …
development among persons over 75 years old. Therefore, there is an urgent need to …
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma
R Golfieri, JI Bilbao, L Carpanese, R Cianni… - Journal of …, 2013 - Elsevier
Background & Aims The European Network on Radioembolization with Yttrium-90 resin
microspheres study group (ENRY) conducted a retrospective study to evaluate the outcomes …
microspheres study group (ENRY) conducted a retrospective study to evaluate the outcomes …
[HTML][HTML] Treatment for hepatocellular carcinoma in elderly patients: a literature review
H Nishikawa, T Kimura, R Kita, Y Osaki - Journal of Cancer, 2013 - ncbi.nlm.nih.gov
An aging society means that the number of elderly patients with cancer is predicted to rise in
the future. Hepatocellular carcinoma (HCC) usually develops in patients with hepatitis B …
the future. Hepatocellular carcinoma (HCC) usually develops in patients with hepatitis B …